Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 853

2.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group.

Lung Cancer. 2012 Jun;76(3):362-7. doi: 10.1016/j.lungcan.2011.12.005. Epub 2012 Jan 14.

3.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.

J Clin Oncol. 2009 Jul 10;27(20):3284-9. doi: 10.1200/JCO.2008.20.8181. Epub 2009 May 11.

PMID:
19433684
4.

FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.

Cohen MH, Gootenberg J, Keegan P, Pazdur R.

Oncologist. 2007 Mar;12(3):356-61.

5.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

6.

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).

Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.

Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9. Epub 2006 Oct 10.

PMID:
17031646
7.

Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.

Malhotra B, Evans T, Weiss J, Eaby B, Stonehouse-Lee S, Sherry V, Langer CJ.

Clin Lung Cancer. 2010 May;11(3):192-7. doi: 10.3816/CLC.2010.n.025.

PMID:
20439196
8.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F.

J Clin Oncol. 2004 Jun 1;22(11):2184-91.

PMID:
15169807
9.

Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.

Somer RA, Sherman E, Langer CJ.

Clin Lung Cancer. 2008 Mar;9(2):102-5. doi: 10.3816/CLC.2008.n.015.

PMID:
18501096
10.

Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.

Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, Brahmer JR, Johnson DH, Sandler A.

J Thorac Oncol. 2012 Nov;7(11):1707-12. doi: 10.1097/JTO.0b013e318265b500.

11.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R.

J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21.

12.

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S, Asmar L.

J Thorac Oncol. 2009 Dec;4(12):1537-43. doi: 10.1097/JTO.0b013e3181c0a2f4.

14.

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).

Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1103-10. doi: 10.1007/s00280-013-2301-z. Epub 2013 Sep 22.

PMID:
24057043
16.

Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.

Saito H, Nakagawa K, Takeda K, Iwamoto Y, Ando M, Maeda M, Katakami N, Nakano T, Kurata T, Fukuoka M.

Am J Clin Oncol. 2012 Feb;35(1):58-63. doi: 10.1097/COC.0b013e318201a0f3.

PMID:
21293243
17.

BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.

Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C.

J Thorac Oncol. 2011 Jan;6(1):109-14. doi: 10.1097/JTO.0b013e3181f94ad4.

18.

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R.

Oncologist. 2003;8(4):303-6.

19.
20.

Supplemental Content

Support Center